A tumor-homing peptide (tLyP-1) attached to ferritin nanoparticles improved targeted delivery of paclitaxel to breast tumors in mice, boosting anticancer effects while reducing side effects.
Selective tumor accumulation with lower toxicitytLyP-1 peptide-decorated ferritin nanoparticles concentrated at tumor sites and improved therapeutic outcomes in breast cancer mice
What the researchers found
The tLyP-1-functionalized ferritin nanoparticles (tLyP-1-HFtn-PTX) showed enhanced intracellular delivery and superior cytotoxicity against both SMMC-7721 liver cancer and MDA-MB-231 breast cancer cells compared to unmodified ferritin-PTX. The peptide-decorated nanoparticles also demonstrated better anti-invasion ability and deeper penetration into tumor spheroids.
In live mice with breast cancer xenografts, tLyP-1-HFtn-PTX selectively accumulated at tumor sites and displayed higher therapeutic efficacy with lower systemic toxicity. Notably, the tLyP-1 peptide functioned effectively at the N-terminal of ferritin, contrary to the previous assumption that it only works at the C-terminus.
Why it matters
Targeted drug delivery is one of the biggest challenges in cancer treatment. This study demonstrates that a relatively simple modification — attaching a tumor-homing peptide to a naturally occurring protein cage — can significantly improve chemotherapy targeting. If this approach translates to humans, it could mean more effective cancer treatment with fewer of the debilitating side effects that make chemotherapy so difficult to tolerate.
The numbers in context
tLyP-1 at N-terminal of HFtn; PTX loaded via pH disassembly/assembly; enhanced uptake, cytotoxicity, anti-invasion; lower systemic toxicity
How the study worked
Researchers fused the tLyP-1 peptide to the N-terminal of human H chain ferritin and loaded paclitaxel into the nanocage using a pH-based disassembly/reassembly method. They tested cellular uptake using confocal microscopy and flow cytometry, measured cytotoxicity with MTT assays on breast and liver cancer cells, and assessed anti-migration effects with wound healing assays. Tumor penetration was evaluated using 3D tumor spheroids. In vivo efficacy was tested in BALB/c nude mice bearing MDA-MB-231 breast cancer xenografts.
Who was studied
BALB/c nude mice with MDA-MB-231 breast cancer xenografts; SMMC-7721 and MDA-MB-231 cells in vitro
What this study cannot tell us
Only one tumor model was tested in vivo (breast cancer xenograft in nude mice), which does not reflect the full heterogeneity of human cancers. Immunocompromised mice lack a functioning immune system, so immune-related effects are unknown. Long-term safety data is not available. Manufacturing peptide-decorated ferritin nanoparticles at pharmaceutical scale presents significant technical challenges. The study did not test the approach in combination with standard-of-care regimens.
How to read the evidence
This is a preclinical animal study combining in vitro cell experiments with in vivo mouse xenograft models. While the results are promising, this represents early-stage evidence that is far from clinical application. The single tumor model and immunocompromised mice limit generalizability.
When this study was published
Published in 2021, this study is relatively recent and reflects current approaches in peptide-based nanomedicine for cancer drug delivery.
The bigger picture
Peptide-functionalized nanoparticles represent a growing area of cancer nanomedicine. This study contributes to the field by showing that ferritin — a biocompatible, naturally occurring protein — can serve as an effective drug delivery vehicle when combined with tumor-penetrating peptides. The unexpected finding that tLyP-1 works at the N-terminal (not just C-terminal) expands the design possibilities for future peptide-nanoparticle systems.
Questions still open
- Can tLyP-1-decorated ferritin nanoparticles deliver other chemotherapy drugs beyond paclitaxel with similar success?
- How would the immune system in immunocompetent animals respond to repeated doses of these protein-based nanoparticles?
- What manufacturing hurdles need to be overcome to bring peptide-functionalized ferritin nanoparticles to clinical trials?
Common questions
What is a tumor-homing peptide and how does it work?
Why use ferritin as a drug delivery vehicle instead of synthetic nanoparticles?
Read the original research
tLyP-1 Peptide Functionalized Human H Chain Ferritin for Targeted Delivery of Paclitaxel.
International journal of nanomedicine, 16, 789-802
Citation
Ma, Yuanmeng; Li, Ruike; Dong, Yixin; You, Chaoqun; Huang, Shenlin; Li, Xun; Wang, Fei; Zhang, Yu. (2021). tLyP-1 Peptide Functionalized Human H Chain Ferritin for Targeted Delivery of Paclitaxel.. International journal of nanomedicine, 16, 789-802. https://doi.org/10.2147/IJN.S289005